سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Mozayeni, Farnaz, Rezaee, Seyed Abdolrahim, Jabbari Azad, Farahnaz, Shabestari, Mahmoud, Faridhosseini, Reza, Rafatpanah, Houshang, Yousefzadeh, Hadis, Garivani, Yousef Ali, Jarahi, Lida, Valizadeh, Narges, Sabet, Faezah, Moshirahmadi, Sharare, Mohammadi, Fatemeh Sadat, Shabestari, Mohammad. (1399). High proviral load of human T cell lymphotropic virus type-1 facilitates coronary artery diseases. , 23(4), 500-506. doi: 10.22038/ijbms.2020.36317.8649
Farnaz Mozayeni; Seyed Abdolrahim Rezaee; Farahnaz Jabbari Azad; Mahmoud Shabestari; Reza Faridhosseini; Houshang Rafatpanah; Hadis Yousefzadeh; Yousef Ali Garivani; Lida Jarahi; Narges Valizadeh; Faezah Sabet; Sharare Moshirahmadi; Fatemeh Sadat Mohammadi; Mohammad Shabestari. "High proviral load of human T cell lymphotropic virus type-1 facilitates coronary artery diseases". , 23, 4, 1399, 500-506. doi: 10.22038/ijbms.2020.36317.8649
Mozayeni, Farnaz, Rezaee, Seyed Abdolrahim, Jabbari Azad, Farahnaz, Shabestari, Mahmoud, Faridhosseini, Reza, Rafatpanah, Houshang, Yousefzadeh, Hadis, Garivani, Yousef Ali, Jarahi, Lida, Valizadeh, Narges, Sabet, Faezah, Moshirahmadi, Sharare, Mohammadi, Fatemeh Sadat, Shabestari, Mohammad. (1399). 'High proviral load of human T cell lymphotropic virus type-1 facilitates coronary artery diseases', , 23(4), pp. 500-506. doi: 10.22038/ijbms.2020.36317.8649
Mozayeni, Farnaz, Rezaee, Seyed Abdolrahim, Jabbari Azad, Farahnaz, Shabestari, Mahmoud, Faridhosseini, Reza, Rafatpanah, Houshang, Yousefzadeh, Hadis, Garivani, Yousef Ali, Jarahi, Lida, Valizadeh, Narges, Sabet, Faezah, Moshirahmadi, Sharare, Mohammadi, Fatemeh Sadat, Shabestari, Mohammad. High proviral load of human T cell lymphotropic virus type-1 facilitates coronary artery diseases. , 1399; 23(4): 500-506. doi: 10.22038/ijbms.2020.36317.8649

High proviral load of human T cell lymphotropic virus type-1 facilitates coronary artery diseases

Iranian Journal of Basic Medical Sciences
مقاله 11، دوره 23، شماره 4، تیر 2020، صفحه 500-506    اصل مقاله (555.41 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2020.36317.8649
نویسندگان
Farnaz Mozayeni1؛ Seyed Abdolrahim Rezaee2؛ Farahnaz Jabbari Azad1؛ Mahmoud Shabestari3؛ Reza Faridhosseini1؛ Houshang Rafatpanah2؛ Hadis Yousefzadeh4؛ Yousef Ali Garivani3؛ Lida Jarahi5؛ Narges Valizadeh2؛ Faezah Sabet2؛ Sharare Moshirahmadi3؛ Fatemeh Sadat Mohammadi1؛ Mohammad Shabestari* 3
1Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2Immunology Research Center, Inflammation and Inflammatory Disease Division, Mashhad University of Medical Sciences, Mashhad, Iran
3Department of Cardiology, Emam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4Immunology Research Center, Bu Ali Research Institute, Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5Addiction Research Center, Mashhad University of Medical Sciences, Faculty of Medicine, Mashhad, Iran
چکیده
Objective(s): Coronary artery disease (CAD) is known as a life threatening disease, worldwide. In this study the role of HTLV-1 infection was evaluated on cardiac involvement in an endemic region of northeastern Iran.
Materials and Methods: Serologic and molecular tests for HTLV-1 infection were carried out in subjects who had coronary angiography. A real-time PCR, TaqMan method, to quantify HTLV-1 proviral load (PVL), and routine hematological and biochemical tests were performed for study subjects.
Results: Twenty nine patients were HTLV-1+CAD+ and 13 cases were HTLV-1+CAD-. Although, there were no significant differences for risk factors like FBS, HDL, triglyceride, systolic and diastolic blood pressure (Cbp, Dbp), waist circumference (WC), hip circumference (WL), cholesterol  (P=0.003), and LDL (P=0.007) levels, and monocyte count (P=0.05) had meaningful differences. The mean HTLV-1 PVL in HTLV-1+CAD+ subjects was 992.62±120 which was higher compared with HTLV-1+CAD- group (406.54±302 copies/104 PBMCs). Moreover, HTLV-1 PVL in males (833±108) was lower compared with females (1218±141 copies/104 PBMCs) (P=0.05). Patients with HTLV-1-PVL of more than 500 copies/104 had more diffused atherosclerosis plaque than patients with less than 500 (OR=6.87, 95% CI=1.34-35.05; P=0.016). Furthermore, patients with diffused coronary atherosclerosis had significantly higher levels of HTLV-1 PVL than patients with middle, proximal, and normal location of coronary sclerotic lesions (P<0.05).
Conclusion: Taken together, in endemic area, HTLV-1 infection, more likely is a facilitating factor for heart complications and the high HTLV-1 PVL might affect CAD manifestations.
کلیدواژه‌ها
Cardiac involvement؛ Coronary artery disease HTLV-1؛ HTLV-1 Proviral load؛ Real-time PCR
مراجع
1. Nizal Sarrafzadegan M, Sadeghi M, Shahram Oveisgharan M, Marshall T. Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study. Arch Iran Med 2013; 16:138.
2. World Health Organization. Global status report on noncommunicable diseases 2010 World Health Organization. Geneva, Switzerland 2011.
3.  Ebrahimi M, Kazemi-Bajestani S, Ghayour-Mobarhan M, Ferns G. Coronary artery disease and its risk factors status in Iran: A review.
Iran Red Crescent Med J 2011; 13:610-623.
4. Alizadehsani R, Habibi J, Bahadorian B, Mashayekhi H, Ghandeharioun A, Boghrati R, et al. diagnosis of coronary arteries stenosis using data mining. J Med Signals Sens 2012; 2:153.
5. Silventoinen K, Magnusson PK, Tynelius P, Batty GD, Rasmussen F. Association of body size and muscle strength with incidence of coronary heart disease and cerebrovascular diseases: a population-based cohort study of one million Swedish men. Int J Epidemiol 2009; 38:110-118.
6. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83:456S-460S.
7. Miller GE, Freedland KE, Duntley S, Carney RM. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am J Cardiol 2005; 95:317-321.
8. Siddiqui T, Dikshit D. Platelets and atherothrombosis: causes, targets and treatments for thrombosis. Curr Med Chem 2013; 20:2779-2797.
9. Liao X, Sluimer JC, Wang Y, Subramanian M, Brown K, Pattison JS, et al. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab 2012; 15:545-553.
10. Shabestari MM, Jabbari F, Gohari B, Moazen N, Azizi H, Moghiman T, et al. Coronary artery angiographic changes in veterans poisoned by mustard gas. Cardiology 2011; 119:208-213.
11. Siegel D, Devaraj S, Mitra A, Raychaudhuri SP, Raychaudhuri SK, Jialal I. Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol 2013; 44:194-204.
12. Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009; 30:2838-2844.
13. Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, Biasucci LM, et al. CDC/AHA Workshop on markers of inflammation and cardiovascular disease application to clinical and public health practice: Report from the laboratory science discussion group. Circulation 2004; 110:e545-e549.
14. Hassanzadeh M, Faridhosseini R, Mahini M, Faridhosseini F, Ranjbar A. Serum levels of TNF-, IL-6, and selenium in patients with acute and chronic coronary artery disease. Iran J Immunol 2006; 3:142-145.
15. Bergstrom I, Backteman K, Lundberg A, Ernerudh J, Jonasson L. Persistent accumulation of interferon-gamma-producing CD8+CD56+ T cells in blood from patients with coronary artery disease. Atherosclerosis 2012; 224:515-520.
16. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000; 101:1785-1791.
17. Shah PK. Link between infection and atherosclerosis: who are the culprits: viruses, bacteria, both, or neither? Circulation 2001; 103:5-6.
18. Rafatpanah H, Farid R, Golanbar G, Azad FJ. HTLV-I Infection: virus structure, immune response to the virus and genetic association studies in HTLV-I-infected individuals. Iran J Allergy Asthma Immunol 2006; 5:153-166.
19. Treviño A, Aguilera A, Caballero E, Benito R, Parra P, Eiros JM, et al. Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain. Virol J 2012; 9:71-75.
20. Vakili R, Sabet F, Aahmadi S, Boostani R, Rafatpanah H, Shamsian A, et al. Human T-lymphotropic Virus Type I (HTLV-I) Proviral Load and Clinical Features in Iranian HAM/TSP Patients: Comparison of HTLV-I Proviral Load in HAM/TSP Patients. Iran J Basic Med Sci 2013; 16:268-272.
21. Azarpazhooh MR, Hasanpour K, Ghanbari M, Rezaee SR, Mashkani B, Hedayati-Moghaddam MR, et al. Human T-lymphotropic virus type 1 prevalence in Northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Retroviruses 2012; 28:1095-1101.
22. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol 2011; 52:172-176.
23. Hedayati-Moghaddam M, Fathimoghadam F, Mashhadi IE, Soghandi L, Bidkhori H. Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran. Iran Red Crescent Med J 2011; 13:424.
24. Foroughipour M, Azad FJ. Outcome of intravenous immunoglobulin-transmitted HTLV-I, hepatitis B, hepatitis C, and HIV infections. Iran J Basic Med Sci 2013; 16:221-224.
25. FaridHosseini R, Jabbari F, Shabestari M, Rezaee SA, Gharivani Y, Valizadeh N, et al. Human T lymphotropic virus type I (HTLV-I) is a risk factor for coronary artery disease. Iran J Basic Med Sci 2013; 16:217-220.
26. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol 2012; 250:87-93.
27. Rafatpanah H, Torkamani M, Valizadeh N, Vakili R, Meshkani B, Khademi H, et al. Prevalence and phylogenetic analysis of HTLV-1 in a segregated population in Iran. J Med Virol 2016; 88:1247-1253.
28. Gabarre J, Gessain A, Raphael M, Merle-Beral H, Dubourg O, Fourcade C, et al. Adult T-cell leukemia/lymphoma revealed by a surgically cured cardiac valve lymphomatous involvement in an Iranian woman: clinical, immunopathological and viromolecular studies. Leukemia 1993; 7:1904-1909.
29. Wang T, Yi R, Green LA, Chelvanambi S, Seimetz M, Clauss M. Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat. Cardiovasc Pathol 2015; 24:279-282.
30. Sabouri AH, Saito M, Usuku K, Bajestan SN, Mahmoudi M, Forughipour M, et al. Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals. J Gen Virol 2005; 86:773-781.
31. Prado F, Prado R, Ladeia AMT. Cardiovascular risk profile in patients with myelopathy associated with HTLV-1. Braz J Infect Dis 2017; 21:226-233.
32. Iemura A, Yano H, Kojiro M, Nouno R, Kouno K. Massive cardiac involvement of adult T-cell leukemia/lymphoma. An autopsy case. Arch Pathol Lab Med 1991; 115:1052-1054.
33. Daisley H, Charles WP. Fatal metastatic calcification in a patient with HTLV-1-associated lymphoma. West Indian Med J 1993; 42:37-39.
34. Daisley H, Charles W. Cardiac involvement with lymphoma/leukemia: a report of three autopsy cases. Leukemia 1997; 11:522-524.
35. Boostani R, Vakili R, Hosseiny SS, Shoeibi A, Fazeli B, Etemadi MM, et al. Triple therapy with prednisolone, pegylated interferon and sodium valproate improves clinical outcome and reduces human T-cell leukemia virus type 1 (HTLV-1) proviral load, tax and HBZ mRNA expression in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Neurotherapeutics 2015; 12:887-895.
36. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol 2012; 250:87-93.
37. Akbarin MM, Rahimi H, Hassannia T, Shoja Razavi G, Sabet F, Shirdel A. Comparison of HTLV-I proviral load in adult T cell leukemia/lymphoma (ATL), HTLV-I-associated myelopathy (HAM-TSP) and healthy carriers. Iran J Basic Med Sci 2013; 16:208-212.
38. Rafatpanah H, Felegari M, Azarpazhooh MR, Vakili R, Rajaei T, Hampson I, et al. Altered expression of CXCR3 and CCR6 and their ligands in HTLV-1 carriers and HAM/TSP patients. J Med Virol 2017; 89:1461-1468.
39. Curis C, Percher F, Jeannin P, Montange T, Chevalier SA, Seilhean D, et al. Human T-lymphotropic virus type 1-induced overexpression of activated leukocyte cell adhesion molecule (ALCAM) facilitates trafficking of infected lymphocytes through the blood-brain barrier. J Virol 2016; 90:7303-7312.
40. Afonso PV, Ozden S, Cumont MC, Seilhean D, Cartier L, Rezaie P, et al. Alteration of blood-brain barrier integrity by retroviral infection. PLoS Pathog 2008; 4:e1000205.

آمار
تعداد مشاهده مقاله: 552
تعداد دریافت فایل اصل مقاله: 382